Steven Seedhouse
Stock Analyst at Raymond James
(2.84)
# 825
Out of 5,182 analysts
174
Total ratings
49.4%
Success rate
5.03%
Average return
Main Sectors:
Stocks Rated by Steven Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRRO Korro Bio | Upgrades: Outperform | $23 | $12.59 | +82.68% | 4 | Mar 13, 2026 | |
| DNTH Dianthus Therapeutics | Upgrades: Strong Buy | $63 → $123 | $90.24 | +36.30% | 5 | Mar 10, 2026 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Overweight | $24 → $26 | $9.03 | +187.93% | 2 | Oct 15, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Strong Buy | $77 → $82 | $105.81 | -22.50% | 20 | Aug 7, 2025 | |
| WVE Wave Life Sciences | Initiates: Overweight | $10 | $7.18 | +39.28% | 3 | Apr 29, 2025 | |
| PHVS Pharvaris | Initiates: Overweight | $28 | $30.02 | -6.73% | 1 | Apr 29, 2025 | |
| IFRX InflaRx | Initiates: Overweight | $10 | $1.97 | +407.61% | 14 | Apr 29, 2025 | |
| VKTX Viking Therapeutics | Initiates: Overweight | $104 | $31.31 | +232.16% | 20 | Apr 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Outperform | $90 → $22 | $5.14 | +328.02% | 2 | Dec 11, 2024 | |
| PRQR ProQR Therapeutics | Upgrades: Strong Buy | $6 → $14 | $1.63 | +758.90% | 6 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $93 | $133.48 | -30.33% | 9 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $57 → $68 | $34.52 | +96.99% | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $67 → $106 | $40.97 | +158.73% | 15 | Jan 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $12 → $15 | $7.13 | +110.38% | 2 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $27 → $56 | $17.47 | +220.55% | 4 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $57 | $13.31 | +328.25% | 10 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $20 → $22 | $5.18 | +324.71% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $17 | $3.04 | +459.21% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $35 | $3.54 | +888.70% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $38 | $82.71 | -54.06% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $30 → $71 | $12.91 | +449.96% | 4 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $5 | $0.34 | +1,388.10% | 5 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $38 | $69.28 | -45.15% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $8.41 | - | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $10.22 | - | 14 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.59 | - | 5 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $285 → $270 | $18.08 | +1,393.36% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $189.13 | - | 2 | Apr 23, 2020 |
Korro Bio
Mar 13, 2026
Upgrades: Outperform
Price Target: $23
Current: $12.59
Upside: +82.68%
Dianthus Therapeutics
Mar 10, 2026
Upgrades: Strong Buy
Price Target: $63 → $123
Current: $90.24
Upside: +36.30%
BioCryst Pharmaceuticals
Oct 15, 2025
Maintains: Overweight
Price Target: $24 → $26
Current: $9.03
Upside: +187.93%
Mirum Pharmaceuticals
Aug 7, 2025
Maintains: Strong Buy
Price Target: $77 → $82
Current: $105.81
Upside: -22.50%
Wave Life Sciences
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $7.18
Upside: +39.28%
Pharvaris
Apr 29, 2025
Initiates: Overweight
Price Target: $28
Current: $30.02
Upside: -6.73%
InflaRx
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $1.97
Upside: +407.61%
Viking Therapeutics
Apr 28, 2025
Initiates: Overweight
Price Target: $104
Current: $31.31
Upside: +232.16%
Q32 Bio
Dec 11, 2024
Downgrades: Outperform
Price Target: $90 → $22
Current: $5.14
Upside: +328.02%
ProQR Therapeutics
Oct 29, 2024
Upgrades: Strong Buy
Price Target: $6 → $14
Current: $1.63
Upside: +758.90%
Jul 8, 2024
Upgrades: Outperform
Price Target: $93
Current: $133.48
Upside: -30.33%
May 10, 2024
Maintains: Strong Buy
Price Target: $57 → $68
Current: $34.52
Upside: +96.99%
Jan 11, 2024
Maintains: Strong Buy
Price Target: $67 → $106
Current: $40.97
Upside: +158.73%
Jan 9, 2024
Maintains: Strong Buy
Price Target: $12 → $15
Current: $7.13
Upside: +110.38%
Jan 4, 2024
Maintains: Strong Buy
Price Target: $27 → $56
Current: $17.47
Upside: +220.55%
Nov 10, 2023
Maintains: Outperform
Price Target: $78 → $57
Current: $13.31
Upside: +328.25%
Aug 15, 2023
Maintains: Strong Buy
Price Target: $20 → $22
Current: $5.18
Upside: +324.71%
Jun 13, 2023
Upgrades: Outperform
Price Target: $17
Current: $3.04
Upside: +459.21%
May 5, 2023
Maintains: Outperform
Price Target: $33 → $35
Current: $3.54
Upside: +888.70%
May 5, 2023
Upgrades: Outperform
Price Target: $38
Current: $82.71
Upside: -54.06%
Dec 15, 2022
Maintains: Strong Buy
Price Target: $30 → $71
Current: $12.91
Upside: +449.96%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $5
Current: $0.34
Upside: +1,388.10%
Nov 9, 2022
Maintains: Outperform
Price Target: $30 → $38
Current: $69.28
Upside: -45.15%
Aug 10, 2022
Downgrades: Underperform
Price Target: n/a
Current: $8.41
Upside: -
Aug 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $10.22
Upside: -
May 18, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $0.59
Upside: -
Aug 6, 2021
Maintains: Outperform
Price Target: $285 → $270
Current: $18.08
Upside: +1,393.36%
Apr 23, 2020
Downgrades: Sell
Price Target: n/a
Current: $189.13
Upside: -